Key Highlights
- Orpyx® announces $20 million in growth capital, led by Perceptive Advisors.
- Orpyx Sensory Insole system provides continuous remote monitoring for diabetic foot complications.
- Partnership with Perceptive Advisors aims to prevent diabetic foot ulcers and amputations.
- Funds will accelerate commercial expansion and improve patient outcomes.
Source: Business Wire
Notable Quotes
- “We’re proud to partner with Perceptive Advisors, whose belief in our mission will help us make an even greater impact on the lives of people managing diabetes.” — Dr. Breanne Everett, CEO at Orpyx
- “Orpyx is an innovator in diabetic foot ulcer prevention…We are excited to partner with the company to support the mission of improving the lives of people at risk from the impacts of peripheral neuropathy and diabetes.” — Sam Chawla, Portfolio Manager at Perceptive Advisors
SoHC's Take
This partnership marks a significant step forward in the field of diabetic foot care, with Orpyx leveraging both capital and strategic backing from Perceptive Advisors. The advanced capabilities of the Orpyx® Sensory Insole system, which provides continuous remote monitoring, represent a transformative innovation in preventing life-altering diabetic complications such as foot ulcers and amputations. The infusion of growth capital will undoubtedly fuel Orpyx’s mission to scale its impact, particularly as the company expands its presence in key healthcare markets. This advancement has the potential to enhance the quality of life for countless individuals managing diabetes and neuropathy.
